The Food and Drug Administration (FDA) is reminding healthcare providers
and patients about the need to enroll
in the Avandia-Rosiglitazone Medicines Access Program by November 17, 2011
in order to continue prescribing and receiving rosiglitazone-containing medicines (Avandia, Avandamet, and Avandaryl). After November 18, 2011, rosiglitazone medicines will no longer be available through retail pharmacies
and will only be available by mail order through specially certified pharmacies participating in the program.
The use of rosiglitazone-containing medicines is limited to patients with type 2 diabetes who are already being successfully treated with these medications, or patients whose blood sugar cannot be controlled with other anti-diabetic medicines and who, after consulting with their healthcare professional and being advised of the benefits and risks of rosiglitazone, including the potential elevated risk of myocardial infarction, do not wish to use pioglitazone-containing medicines (Actos, Acotplus Met, Actoplus Met XR, or Duetact).
Go to FDA’s website for additional information.